Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sun Yat-sen University
For HBeAg positive hepatitis B patients who have been treated by entecavir for 48 weeks but without HBeAg loss, switching to peg-interferon may increase the response rate. In our study, patients without HBeAg loss to 48 weeks entecavir treatment were divided into two groups. In Group A, patients continued entecavir for another 72 weeks. In Group B, patients switched to peg-interferon-2a monotherapy for 48 weeks, then followed up 24 weeks.
Age
18–50
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age between 18 and 50 years old
HBsAg(+) and HBeAg(+) for over 6 months before entecavir treatment
Treated by entacavir for 48 weeks with HBeAg seroconversion